Genetically engineered bacterium for efficiently expressing beta-glucosidase and application of genetically engineered bacterium
The genetically engineered bacteria expressing β-glucosidase was constructed through CRISPR/Cas9 gene editing technology, which solved the problem of efficient introduction of β-glucosidase in RA treatment in the prior art, and achieved improvement of isoflavones bioavailability and reduction of treatment The cost effect provides a new treatment plan for rheumatoid arthritis.
Patent Information
- Application Number
- CN202410979138.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-22
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-07-22
AI Technical Summary
The prior art is difficult to efficiently introduce β-glucosidase into RA treatment, resulting in poor treatment effects and high cost, and some patients develop drug resistance to existing drugs.
Primers were designed to amplify the β-glucosidase gene and integrate it into the genome of E. coli Nissle 1917 to construct genetically engineered bacteria expressing β-glucosidase to achieve their efficient expression.
Increased the bioavailability of active compounds such as isoflavones, reduced treatment costs, and reduced drug side effects, providing a new treatment pathway for rheumatoid arthritis.
Smart Images

Figure CN118910111A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of bioengineering, and in particular to a genetically engineered bacterium capable of efficiently expressing beta-glucosidase and an application thereof. Background Art
[0002] Rheumatoid arthritis (RA) is an autoimmune disease with more than 46 million patients worldwide, which poses a significant burden on society and the economy. RA is mainly manifested by persistent inflammation of the joints, which causes pain and swelling, and can lead to joint deformity and loss of function over time. Current treatments for RA mainly rely on nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), biologics, and corticosteroids. Although these methods can slow the progression of the disease and control symptoms to a certain extent, long-term use may lead to side effects such as gastrointestinal discomfort, cardiovascular problems, and potential infection risks. In addition, these treatment options are usually costly and are not sustainable for many patients. In addition, some patients may develop resistance to existing drugs or have poor drug effects, and new treatments are urgently needed. Therefore, finding a safe and economical treatment strategy is an important research direction in the current field of RA treatment.
[0003] In recent years, advances in genetic engineering technology have provided new ways to treat various diseases, especially CRISPR / Cas9 gene editing technology, which has become a powerful tool for biomedical research due to its precision, high efficiency and ease of operation. Although CRISPR / Cas9 has achieved initial results in the treatment of genetic diseases, its application in chronic inflammatory diseases, especially RA, is still in the exploratory stage.
[0004] β-Glucosidase is an enzyme that can break down glucosides and release active compounds such as isoflavones. In the treatment of RA, increasing the bioavailability of components such as isoflavones may be an effective means to alleviate symptoms and disease progression. Currently, although studies have pointed out the potential of β-glucosidase in improving the bioavailability of drugs, how to efficiently introduce such enzymes into treatment remains a challenge. Summary of the invention
[0005] The purpose of the present invention is to overcome the deficiencies of the prior art and provide a genetically engineered bacterium for efficiently expressing β-glucosidase and its application.
[0006] To achieve the above object, the technical solution adopted by the present invention is: a method for constructing a genetically engineered bacterium expressing β-glucosidase, comprising the following steps:
[0007] (1) Design primers to amplify the β-glucosidase gene;
[0008] (2) designing primers to clone the promoter nirB gene and the upstream homology arm and downstream homology arm of the attλ site from the E. coli genome;
[0009] (3) Design primers to clone the gRNA sequence from the pTargetF plasmid;
[0010] (4) Linearize the pTargetF plasmid using primers;
[0011] (5) constructing the gRNA, the upstream homology arm of the attλ site, the promoter nirB gene, the β-glucosidase gene and the downstream homology arm of the attλ site into the linearized pTargetF plasmid backbone in sequence through homologous recombination to obtain the recombinant plasmid pTargetF-bGC;
[0012] (6) The pCas plasmid is transferred into competent Escherichia coli cells to obtain competent cells that have successfully integrated the pCas plasmid; and the recombinant plasmid pTargetF-bGC is then transferred into competent cells that have successfully integrated the pCas plasmid to obtain the genetically engineered bacteria that express β-glucosidase.
[0013] The present invention is based on CRISPR / Cas9-mediated gene editing technology, and synthesizes the pTargetF-bGC plasmid through primer design. The β-glucosidase gene is integrated into the genome of E. coli Nissle 1917 through the pTargetF-bGC plasmid to achieve stable and high-quality expression of the β-glucosidase.
[0014] As a preferred embodiment of the method for constructing a genetically engineered bacterium expressing β-glucosidase of the present invention, the nucleotide sequences of the primers used to amplify the β-glucosidase gene in step (1) are shown in SEQ ID NO: 1 and SEQ ID NO: 2.
[0015] As a preferred embodiment of the method for constructing a genetically engineered bacterium expressing β-glucosidase according to the present invention, in the step (2), the nucleotide sequences of the primers used for cloning the promoter nirB gene are shown in SEQ ID NO: 3 and SEQ ID NO: 4; the nucleotide sequences for cloning the homologous arms upstream of the attλ site are shown in SEQ ID NO: 5 and SEQ ID NO: 6; and the nucleotide sequences for cloning the homologous arms downstream of the attλ site are shown in SEQ ID NO: 7 and SEQ ID NO: 8.
[0016] As a preferred embodiment of the method for constructing a genetically engineered bacterium expressing β-glucosidase according to the present invention, in the step (3), the nucleotide sequences of the primers used to clone the gRNA sequence are shown in SEQ ID NO: 9 and SEQ ID NO: 10.
[0017] As a preferred embodiment of the method for constructing a genetically engineered bacterium expressing β-glucosidase according to the present invention, in the step (4), the nucleotide sequences of the primers used for linearizing the pTargetF plasmid are shown in SEQ ID NO: 11 and SEQ ID NO: 12.
[0018] As a preferred embodiment of the method for constructing a genetically engineered bacterium expressing β-glucosidase according to the present invention, the β-glucosidase gene in step (1) is cloned from Parabacteroides distichous.
[0019] As a preferred embodiment of the method for constructing a genetically engineered bacterium expressing β-glucosidase according to the present invention, the Escherichia coli in step (6) is E. coli Nissle 1917.
[0020] The present invention also provides a genetic engineering bacterium expressing beta-glucosidase constructed by the construction method.
[0021] The present invention also provides the use of the genetically engineered bacteria expressing beta-glucosidase in preparing a medicine for treating rheumatoid arthritis.
[0022] The present invention also provides a pharmaceutical composition for treating rheumatoid arthritis, wherein the pharmaceutical composition comprises the genetically engineered bacteria expressing beta-glucosidase.
[0023] Beneficial effects of the present invention: The present invention provides a method for genetically modifying a recognized probiotic bacterium, Escherichia coli (E. coli Nissle 1917), based on CRISPR / Cas9 technology to construct a new genetically engineered bacterium, which achieves efficient expression of β-glucosidase. The genetically engineered bacterium is applied to the treatment of rheumatoid arthritis, which can improve the bioavailability of active molecules, reduce treatment costs, and reduce drug side effects, thereby providing a new approach for the treatment of rheumatoid arthritis and having good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 :A is the construction process of the genetically engineered bacteria that efficiently express β-glucosidase in Example 1; B is the PCR detection of the expression level of the target gene β-GC; C is the β-GC enzyme activity detection result; D is the content detection result of the isoflavone daidzein (GLY) in each group of incubation solutions in Example 2.
[0025] Figure 2:A is the detection result of the content of isoflavone daidzein (GLY) in mouse feces; B is the results of HE staining to detect the inflammation and pathological changes of the joints of each group of mice; C is the detection result of the content of isoflavone daidzein (GLY) in mouse serum; D is the level of IL-6 in serum detected by ELISA; E is the level of TNF-α in serum detected by ELISA; F is the proportion of joint macrophages detected by flow cytometry; G is the proportion of neutrophils detected by flow cytometry. *P<0.05; **P<0.01 DETAILED DESCRIPTION
[0026] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention.
[0027] Example 1 Construction of genetically engineered bacteria that efficiently express β-glucosidase
[0028] 1. Construction of plasmid
[0029] A. PCR cloning of target genes and sequences
[0030] (1) Primers F1 and R1 were used to clone the β-glucosidase gene from Parabacteroides dissimilar ATCC 8503 (purchased from Guangdong Microbial Culture Collection Center), wherein the sequences of primers F1 and R1 are:
[0031] F1: 5'-cctgtgcagctcaggaggaaggagaATGAACAAACTATTAATGGGCGC-3' (SEQ ID NO: 1);
[0032] R1: 5'-gtttcgctcaagttagtatCTATCTTTTCAGAAGATCGATCCTCTC-3' (SEQ ID NO: 2).
[0033] (2) The promoter nirB gene was cloned from Escherichia coli Nissle 1917 (purchased from Wuhan Miaoling Biotechnology) using primers F2 and R2, wherein the sequences of primers F2 and R2 are:
[0034] F2: 5'-ATGAGCAAAGTCAGACTCGCAATTATC-3' (SEQ ID NO: 3);
[0035] R2: 5'-ctcctgagctgcacaggaactcgagtTCATGCGTTGTCCTCCACCAGAG-3' (SEQ ID NO: 4).
[0036] (3) Using primers F3 and R3, the upstream homology arm of the attλ site was cloned from Escherichia coli Nissle 1917, wherein the sequences of primers F3 and R3 are:
[0037] F3: 5'-tctagagtcgacctgcagGGAAAGCCCAATCTTCACATCAATC-3' (SEQ ID NO: 5);
[0038] R3: 5'-gagtctgactttgctcatAAAAAAGCAGGCTTCAACG-3' (SEQ ID NO: 6).
[0039] (4) Using primers F4 and R4, clone the downstream homology arm of the attλ site from Escherichia coli Nissle 1917, wherein the sequences of primers F4 and R4 are:
[0040] F4: 5'-ATAACTAACTTGAGCGAAAC-3' (SEQ ID NO: 7);
[0041] R4: 5'-gggtaatagatctaagcttTTACGATGGCGATAATATTTC-3' (SEQ ID NO: 8).
[0042] (5) Use primers F5 and R5 to clone the gRNA sequence on the pTargetF plasmid, where the sequences of primers F5 and R5 are:
[0043] F5:5'-AGTCCTAGGTATAATACTAGTTCAAGTTAGTATAAAAAAGCGTTTTAGAG CTAGAAATAG-3' (SEQ ID NO: 9);
[0044] R5: 5'-CTGCAGGTCGACTCTAGAGAATTCAAAAAAAGCAC-3' (SEQ ID NO: 10).
[0045] (6) Using primers F6 and R6, reverse PCR was performed on the pTargetF plasmid to obtain a linearized plasmid, wherein the sequences of primers F6 and R6 are:
[0046] F6: 5'-ACTAGTATTATACCTAGGACTGAGCTAGCTG-3' (SEQ ID NO: 11);
[0047] R6: 5'-AAGCTTAGATCTATTACCCTGTTATCCCTAC-3' (SEQ ID NO: 12).
[0048] The above-mentioned amplification reaction system for cloning each gene and sequence from bacteria / plasmid is shown in Table 1;
[0049] Table 1
[0050] Reagents Dosage 2×Phanta Flash Master Mix(Dye Plus) 25μL Primer F (10 μM) 2μL Primer R (10 μM) 2μL template 1μL bacterial solution / 10ng plasmid <![CDATA[ddH2O]]> Make up to 50 μL
[0051] PCR amplification conditions: 1) 98°C pre-denaturation: 3 minutes; 2) 98°C denaturation: 10 seconds; 3) 60°C annealing: 5 seconds; 4) 72°C extension: 20 seconds; 5) repeat steps 1)-3) for a total of 34 cycles; 6) 72°C final extension: 5 minutes.
[0052] B. Purification of PCR Products
[0053] Use the FastPure Gel DNA Extraction Mini Kit from Novagen to purify the PCR amplification product. The specific steps are as follows:
[0054] (1) Electrophoresis of PCR products on 1% agarose gel;
[0055] (2) Observe the gel under ultraviolet light and cut the gel blocks at the target band positions of each gene and fragment;
[0056] (3) Purify according to the instructions of FastPure Gel DNA Extraction Mini Kit.
[0057] C. Connect the fragments to the plasmid backbone
[0058] The purified gRNA, upstream homology arm, nirB promoter, β-glucosidase gene and downstream homology arm fragment were connected to the linearized pTargetF plasmid backbone by homologous recombination (using ClonExpress Ultra One Step Cloning Kit V2 from Novogene) according to the operating instructions, and finally the plasmid pTargetF-bGC was constructed.
[0059] 2. Construction of engineered bacteria
[0060] Specific experimental methods: Figure 1As shown in A, E.coli Nissle 1917 was selected as the host strain. The strain was cultured in LB medium to the logarithmic growth phase before the experiment to ensure that the bacteria were in an active state for transformation. The bacteria were washed three times with sterile water and resuspended with 10% glycerol to obtain competent cells. The pCas plasmid was transferred into the competent cells of Escherichia coli by electrotransformation, and the electrotransformation conditions were set to 2.5kV / cm voltage and an electrotransformation cup with a 0.2cm electrode spacing. After electrotransformation, the cells were immediately transferred to a test tube containing SOC medium for recovery for 1 hour. The recovered cells were spread on an LB plate containing kanamycin for screening to select cells that successfully integrated the pCas plasmid. The successfully screened bacteria were cultured at 30°C and induced with 10mM arabinose to promote the expression of the λ-Red gene. The above-induced bacteria were used to make competent cells, and the pTargetF-bGC plasmid was transferred by electrotransformation. Subsequently, the bacteria were spread on LB plates containing kanamycin (50ug / mL) and streptomycin (50ug / mL) and cultured overnight at 30°C. The Cas protein was guided by gRNA to the attλ site for cutting, and the promoter and β-glucosidase gene were integrated into the genome of Escherichia coli by homologous recombination. A single clone was picked from the resistant plate and inoculated into LB medium containing 0.5mM IPTG and cultured overnight at 37°C to eliminate the plasmid. The above bacterial solution was inoculated on LB medium by plate streaking. After overnight culture at 37°C, colonies were picked for PCR, and the following primers were used to screen single clones with successful gene integration: forward primer: ATGAACAAACTATTAATGGGCGC, reverse primer: CTATCTTTTCAGAAGATCGATCCTCTC. The PCR product was analyzed by agarose gel electrophoresis, and the bands were observed under ultraviolet light. The negative control had no band; the band size of the positive bacteria was 2352bp, which was the β-glucosidase engineered bacteria with successful gene editing.
[0061] Example 2 Fermentation experiment of genetically engineered bacteria expressing β-glucosidase efficiently
[0062] 1. Detection of β-glucosidase activity: The specific experimental method is as follows: EcN-β-GC group: Take the bacterial solution (5 ml, OD600 = 1) of the engineered bacteria constructed in Example 1 and mix it with 500 mg of soybean powder rich in isoflavone glucoside, and incubate it anaerobically at 37°C for 24 hours; EcN group: Take the bacterial solution (5 ml, OD600 = 1) of E. coli Nissle1917 and mix it with 500 mg of soybean powder rich in isoflavone glucoside, and incubate it anaerobically at 37°C for 24 hours; MCM group: Mix 5 mL of culture medium (LB) with 500 mg of soybean powder rich in isoflavone glucoside, and incubate it anaerobically at 37°C for 24 hours. After the culture, the β-glucosidase activity in the bacterial solution of each group was detected using a β-glucosidase assay kit (Solarbio BC2565, Solarbio), and the operating steps were the same as the kit instructions.
[0063] The results are as follows Figure 1 As shown in C, the β-glucosidase activity of the EcN-β-GC group was 7.8U / 10^6CFU, and the β-glucosidase activity of the EcN group was 1.2U / 10^6CFU. The above results show that the engineered bacteria constructed in Example 1 can efficiently express β-glucosidase.
[0064] 2. Detection of isoflavone daidzein (Glycitein) content:
[0065] (1) Grouping:
[0066] MCM+EcN-β-GC group: Take 100uL of the incubation solution of the above EcN-β-GC group into a new centrifuge tube, add 900uL of methanol and mix well, and centrifuge at 13000g for 15min at 4°C.
[0067] MCM+EcN group: Take 100uL of the incubation solution of the EcN group into a new centrifuge tube, add 900uL of methanol and mix well, and centrifuge at 13000g for 15min at 4°C.
[0068] MCM group: Take 100uL of the incubation solution of the above MCM group into a new centrifuge tube, add 900uL of methanol and mix well, and centrifuge at 13000g for 15min at 4°C.
[0069] (2) LC-MS was used to detect the content of isoflavones (glycitein) in each group: LC-MS analysis was performed using a Shimadzu LCMS-8050 triple quadrupole mass spectrometer (Shimadzu, Kyoto, Japan) and a Shim-pack GIST C18-AQ chromatographic column (Shimadzu, Kyoto, Japan), wherein mobile phase A was 0.1% formic acid in water and mobile phase B was methanol; the elution procedure was as follows: within 0-5 min, mobile phase B was increased from 10% to 100% in a gradient; then the mobile phase B ratio was maintained at 100% within 5-8 min; then within 8-11 min, mobile phase B was decreased from 100% to 10% in a gradient; the flow rate was set at 0.3 mL / min and the injection volume was 10 μL.
[0070] The results are as follows Figure 1 As shown in D, the Glycitein content in the MCM+EcN-β-GC group was significantly higher than that in the background group MCM group and MCM+EcN group.
[0071] Example 3 In vivo verification experiment of the function of genetically engineered bacteria expressing β-glucosidase efficiently
[0072] This example uses a collagen-induced arthritis (CIA) mouse model for in vivo experiments, and the specific experimental steps are as follows:
[0073] 1. Experimental groups: Thirty collagen-induced arthritis (CIA) mice were selected for the animal experiment and divided into three groups: Vehicle group, EcN group and EcN-β-GC group.
[0074] 2. Experimental process: All mice were housed in a temperature-controlled environment with a 12-hour light and 12-hour dark cycle, with free access to water and food. The EcN-β-GC group CIA mice were given 1.0×10^8 CFU of the engineered bacteria constructed in Example 1 by gavage every day for 5 consecutive days; the EcN group CIA mice were given 1.0×10^8 CFU of E. coli Nissle 1917 by gavage every day for 5 consecutive days; and the Vehicle group was given normal saline.
[0075] 3. Detection:
[0076] (1) After oral administration on the 5th day, stool samples of mice were collected and the glycitein content in the stool was analyzed by LC-MS. The LC-MS analysis was performed using a Shimadzu LCMS-8050 triple quadrupole mass spectrometer (Shimadzu, Kyoto, Japan) and a Shim-pack GIST C18-AQ chromatographic column (Shimadzu, Kyoto, Japan), where mobile phase A was 0.1% formic acid in water and mobile phase B was methanol. The elution procedure was as follows: within 0-5 min, the mobile phase B was increased from 10% to 100% in a gradient; then, the mobile phase B ratio was maintained at 100% within 5-8 min; then, within 8-11 min, the mobile phase B was decreased from 100% to 10% in a gradient; the flow rate was set at 0.3 mL / min, and the injection volume was 10 μL.
[0077] (2) After intragastric administration on the 5th day, HE staining was used to detect joint inflammation and pathological changes. The specific experimental steps are as follows:
[0078] a. Fix the joint tissue in 10% neutral formalin solution for 24 hours;
[0079] b. Dehydrate, make transparent, wax-impregnate and embed the fixed tissue;
[0080] c. Make paraffin sections with a thickness of 5 μm;
[0081] d. Dewax and hydrate the slices in sequence;
[0082] e. Stain with hematoxylin for 5-10 minutes and rinse with running water;
[0083] f. Differentiate with 1% hydrochloric acid ethanol for a few seconds, then wash with tap water;
[0084] g. Stain with 0.5% eosin for 1-2 minutes and rinse with running water;
[0085] h. Dehydration, transparency and sealing;
[0086] i. Observe and take photos under a microscope;
[0087] (3) After intragastric administration on the 5th day, the levels of IL-6 and TNF-α in mouse serum were detected by ELISA. The specific experimental steps were as follows: serum samples of mice were collected and Biolegend LEGEND MAX TM Mouse IL-6 ELISA Kit (Cat. No. 431307) and Biolegend LEGEND MAX TMMouse TNF-α ELISA Kit (Cat. No. 430907) was used to detect serum IL-6 and TNF-α levels according to the kit instructions. (4) After intragastric administration on the 5th day, the proportion of joint macrophages and neutrophils was detected by flow cytometry. The specific experimental steps are as follows:
[0088] a. Remove the connective tissue from the joint tissue with forceps, immerse it in 1640 culture medium and digest it with type IV collagenase (final concentration 1 mg / mL) at 37°C for 2 h.
[0089] b. Prepare a six-well plate and a 70um mesh, pour the claws and digestion solution into the mesh, and grind gently with a grinding rod to prepare a single-cell suspension.
[0090] c. Wash the cells with PBS and remove the supernatant by centrifugation.
[0091] d. Block the cells with Fc Block and incubate at room temperature for 10 minutes.
[0092] e. Add fluorescently labeled antibodies (CD11b, F4 / 80, Ly6G) and incubate at room temperature in the dark for 30 minutes.
[0093] f. Wash the cells, remove the supernatant by centrifugation, and resuspend in PBS.
[0094] g. Load the sample onto flow cytometer to detect the ratio of macrophages and neutrophils.
[0095] The results are as follows Figure 2 As shown. Figure 2 A shows that the glycitein content in the stool samples of mice in the EcN-β-GC group (3.5 ng / mg) was significantly higher than that in the EcN group (1.1 ng / mg); Figure 2 HE staining of B showed that the degree of joint tissue inflammation in the EcN group and EcN-β-GC group was significantly reduced compared with the Vehicle group. ELISA results showed that the concentrations of IL-6 and TNF-α in the serum of the EcN group and EcN-β-GC group were significantly lower than those of the Vehicle group ( Figure 2 CE). Flow cytometry analysis showed that the proportions of macrophages and neutrophils in the EcN group and EcN-β-GC group were significantly lower than those in the Vehicle group ( Figure 2 FG). As can be seen from the above, the engineered bacteria constructed in Example 1 of the present invention can significantly reduce the joint inflammation response of CIA model mice by reducing the level of inflammatory factors and inflammatory cell infiltration.
[0096] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.
Claims
1. A method for constructing a genetically engineered bacterium expressing β-glucosidase, characterized in that: The following steps are involved: (1) Design primers to amplify the β-glucosidase gene; (2) designing primers to clone the promoter nirB gene and the upstream homology arm and downstream homology arm of the attλ site from the E. coli genome; (3) Design primers to clone the gRNA sequence from the pTargetF plasmid; (4) Linearize the pTargetF plasmid using primers; (5) constructing the gRNA, the upstream homology arm of the attλ site, the promoter nirB gene, the β-glucosidase gene and the downstream homology arm of the attλ site into the linearized pTargetF plasmid backbone in sequence through homologous recombination to obtain the recombinant plasmid pTargetF-bGC; (6) Transforming the pCas plasmid into competent E. coli cells to obtain competent cells that have successfully integrated the pCas plasmid; The recombinant plasmid pTargetF-bGC is then transferred into competent cells that have successfully integrated the pCas plasmid to obtain the genetically engineered bacteria expressing β-glucosidase.
2. The method for constructing a genetically engineered bacterium expressing β-glucosidase according to claim 1, characterized in that: The nucleotide sequences of the primers used to amplify the β-glucosidase gene in step (1) are shown in SEQ ID NO: 1 and SEQ ID NO:
2.
3. The method for constructing a genetically engineered bacterium expressing β-glucosidase according to claim 1, characterized in that: In the step (2), the nucleotide sequences of the primers used to clone the promoter nirB gene are shown in SEQ ID NO: 3 and SEQ ID NO: 4; the nucleotide sequences of the primers used to clone the homology arms upstream of the attλ site are shown in SEQ ID NO: 5 and SEQ ID NO: 6; and the nucleotide sequences of the primers used to clone the homology arms downstream of the attλ site are shown in SEQ ID NO: 7 and SEQ ID NO:
8.
4. The method for constructing a genetically engineered bacterium expressing β-glucosidase according to claim 1, characterized in that: In the step (3), the nucleotide sequences of the primers used to clone the gRNA sequence are shown in SEQ ID NO: 9 and SEQ ID NO:
10.
5. The method for constructing a genetically engineered bacterium expressing β-glucosidase according to claim 1, characterized in that: In the step (4), the nucleotide sequences of the primers used to linearize the pTargetF plasmid are shown in SEQ ID NO: 11 and SEQ ID NO:
12.
6. The method for constructing a genetically engineered bacterium expressing β-glucosidase according to claim 1, characterized in that: The β-glucosidase gene in the step (1) is cloned from Parabacteroides distichous.
7. The method for constructing a genetically engineered bacterium expressing β-glucosidase according to claim 1, characterized in that: The Escherichia coli in step (6) is E. coli Nissle 1917.
8. A genetically engineered bacterium expressing β-glucosidase constructed according to the construction method according to any one of claims 1 to 7.
9. Use of the genetically engineered bacteria expressing β-glucosidase according to claim 8 in the preparation of a drug for treating rheumatoid arthritis.
10. A pharmaceutical composition for treating rheumatoid arthritis, characterized in that: The pharmaceutical composition comprises the genetically engineered bacteria expressing β-glucosidase according to claim 8.
Citation Information
Patent Citations
Beta-glucosidase gene, coding enzyme, engineering bacterium and application thereof
CN113388628A
Method for obtaining high-yield and high-stability heterologous beta-glucosidase
CN113980938A
Pichia pastoris engineering bacterium for producing beta-glucosidase at high yield and application of pichia pastoris engineering bacterium
CN115851677A
Anaerobic high-yield L-arginine engineering bacterium as well as preparation method and application thereof
CN115960807A
Novel lactic acid bacteria having beta-glucosidase activity and use thereof
KR1020160112699A
